School of Medicine


Showing 41-60 of 152 Results

  • Fumiaki Ikeno

    Fumiaki Ikeno

    Program Director (U.S) Japan Biodesign, Stanford Biodesign, Medicine - Med/Cardiovascular Medicine

    BioProgram Director (U.S) Japan Biodesign, Stanford Biodesign
    Researcher Cardiovascular Medicine, Stanford University
    Faculty of Japan Reach, CARE (Center for Asian Health Research and Education) , Stanford University
    Co-Director of Asia, SPARK Global, Stanford SPARK , Stanford University


    Dr. Ikeno is a Researcher, Cardiovascular Medicine, Stanford University. In this role, he is responsible for pre clinical studies including GLP for medical devices and also regenerative medicines for cardiovascular diseases. Currently, he is devoting himself to the international regulatory project between Japan and the United States, also known as "Harmonization by Doing", whose focus is to collaborate with regulatory agencies such as FDA, PMDA/MHLW, academia and industries for improving the regulatory process in the 2 largest medtech markets. Dr. Ikeno also devoted himself to found Japan biodesign program which is a collaborative program with University of Tokyo, Osaka University, Tohoku University, Japan Federation Medical Device Association, Ministry of Education Japan and Stanford biodesign program. Currently, Dr. Ikeno serves as the Program Director (US) for Japan Biodesign. Dr. Ikeno is co-founder and board member of US-Japan MedTech Frontier which is a non-profit cooperate to make a trans-pacific eco-system of medical device between Japan and USA.

    After 9 years clinical practice as an interventional cardiologist and Family Doctor in rural areas of Japan, Dr. Ikeno came to Stanford as a Researcher and completed his Biodesign Certificate Program. Being part of the ecosystem in Silicon Valley, Dr. Ikeno participated in more than 200 medtech projects and 50 GLP studies as well as in the analysis of clinical trials for cardiovascular medicine (BARI2D, FAME, ReOPEN etc). His other academic consortium projects include Peripheral Academic Research Consortium, Global Consensus Working Group of Optical Coherence Tomography, and Japan-US consensus document for the treatment of critical limb ischemia.

    Over the last decade, Dr. Ikeno has served as an advisor for medical device industries and currently serves as a chief medical officer of an incubation fund specific for medtech (Medventure Partners, Inc, Tokyo) as a spin-off from Innovation Network Corporation of Japan (INCJ) that is the largest government and private partnership fund in Japan. He is also serving as a chair of cardiovascular working group of APAN (Asian Pacific Advanced Network) that contributes the remote education, research activities, and tele-health using a specialized internet network. Dr.Ikeno is also serving as consulting faculty/lecturer roles in several universities in Japan including University of Tokyo, Osaka University, Tsukuba University etc. Dr. Ikeno has authored over 70 peer reviewed publications and textbooks and has been invited to lecture at international medical conferences. Dr. Ikeno is a council member of U.S.- Japan Council which is a non-profit organization by Japanese American. He is serving as a mentor for START-X MED which is an accelerating program for Stanford related entrepreneurs in medical fields.

    Contact Information


    Falk CVRC CV007
    300 Pasteur Drive
    Palo Alto, CA 94305-5406

  • Reza Jarral

    Reza Jarral

    Affiliate, Clinical Excellence Research Center (CERC) Operations

    BioDr. Reza Jarral is a distinguished healthcare leader, primary care physician, and health technologist. He currently serves as the Chief Medical Officer at CareHQ, New Zealand’s largest primary telehealth provider. He is an Affiliated Scholar at the Stanford Clinical Excellence Research Center, where his research and applied work explores the intersection of frontier digital technology, implementation science, and value-based care.

    A former Harkness Fellow at the Commonwealth Fund and DICE Fellow at CERC, Dr. Jarral has extensive international experience spanning clinical operations, digital health innovation, and health equity across the UK, New Zealand, and the United States. He has previously served as the inaugural Clinical Director for Health Equity for New Zealand's largest primary health organization and is an Affiliated Scholar at the Stanford Center for Digital Health, where his work focuses on the ethical, inclusive, and impactful integration of AI and emerging technologies in medicine.

  • Kathy Johnson

    Kathy Johnson

    Executive Administrator, SPARK at Stanford

    Current Role at StanfordProgram Administrator, SPARK at Stanford
    Executive Admin to:
    Daria Mochly-Rosen, Professor
    Kevin V. Grimes, Professor - Teaching
    Department of Chemical & Systems Biology

  • Sharada Kalanidhi

    Sharada Kalanidhi

    Director of Data Science, Biochemistry - Genome Center

    Current Role at StanfordCurrent Research: Mathematical Medicine

    The essential challenge is not merely to solve a problem, but to discover the mathematical framework in which the problem can be understood — a perspective associated with the mathematician Alexander Grothendieck.

    We spent decades using sophisticated mathematics to understand financial markets. What happens when we bring that same mathematical direction—and deeper ideas from pure mathematics—to understanding human biology?

    This question captures the intellectual motivation behind Sharada's current work: developing the foundations of Mathematical Medicine, a proposed new discipline that draws on pure mathematics to address fundamental challenges in individualized diagnosis, personalized therapeutics, cancer treatments, and healthy longevity.

    The work begins with a central challenge in contemporary medicine. Advances in genomics, proteomics, metabolomics, and computational biology have generated unprecedented volumes of biomedical data. Yet translating these measurements into meaningful insights for individual patients remains difficult, particularly for those with rare, complex, or previously unexplained conditions.

    Conventional statistical and machine learning approaches have transformed biomedical research, but their reliance on population-level patterns can limit their usefulness when an individual patient's biology differs substantially from that of available reference cohorts. Clinically meaningful differences may be treated as statistical noise or outliers rather than investigated as potential clues to underlying disease mechanisms.

    After more than a decade of research and collaboration with biochemists at SGTC, Sharada became increasingly interested in whether the mathematical foundations used to interpret biomedical data were sufficient for the complexity of individualized medicine.

    Her central premise is that progress in personalized medicine may require not simply more data or larger computational models, but new mathematical ways of understanding biological systems.

    Rather than applying existing statistical approaches to biomedical problems, Mathematical Medicine explores whether ideas from pure mathematics can fundamentally change how biological questions are formulated, understood, and solved.

    The research is guided by the possibility that deeper mathematical understanding can reveal - and preserve- meaningful biological relationships even when data are limited, heterogeneous, or difficult to interpret using conventional approaches.

    This approach echoes a perspective expressed by the mathematician Mikhail Gromov: “This area does not yet exist. It will have to be invented.”

    It also reflects the empirical philosophy associated with the mathematician and quantitative investor Jim Simons: “We don't start with models. We start with data. We don't have any preconceived notions.” The aim is to allow biological observations to guide mathematical inquiry, rather than forcing them into existing computational frameworks.

    Sharada's research has contributed to investigations of complex and previously unexplained clinical conditions, including cases in which mathematical and multi-omic analyses helped identify potential diagnoses and therapeutic pathways. These investigations also motivate broader questions about how individual biological differences can inform our understanding of disease.

    The long-term vision is to establish Mathematical Medicine as a rigorous discipline connecting pure mathematics, molecular biology, and clinical medicine—advancing mathematics toward a foundation for understanding individual biology, preserving biological mechanisms and informing clinical decisions.

    Further information about Mathematical Medicine, its research vision, and opportunities for early philanthropic partnerships is available at:

    https://mathmed-2026.web.app/